Advances in Radiotherapy and Prognosis

Dear Colleagues,

Radiotherapy plays an important role in cancer treatment and has progressed toward personalization. In addition to improving accuracy using advanced technology, it is also very important to identify patients with a high risk of recurrence. These patients need more aggressive treatments, such as chemotherapy, target therapy, and immunotherapy. This relies on the use of clinical information and blood laboratory data. Additionally, pathological information from immunohistochemistry (IHC) and genetic alteration is useful for the evaluation of prognosis. The high and low levels of these biomarkers can be used to classify patients at risk of recurrence for the basis of future clinical trials to changes in radiation dose escalation/de-escalation or treatment volume. This Special Issue will focus on the clinical treatment effects of the above concepts. In addition, various precise treatments, such as particle therapy and stereotactic body radiotherapy (SBRT) and comparison of the effects of different radiation doses/volumes, are welcome in terms of treatment technology. Original and review articles are welcome to enrich the literature and the scientific community.

Prof. Eng-Yen Huang
Prof. Dr. Yi-Wei Chen
Topic Editors